My Companies
Notification
Account
Log Out
Login
Sun Pharma licensed ex-US/China rights to manufacture and commercialize once-monthly PCSK9 inhibitor lerodalcibep, EU-approved Sept 21 as Lyrokaul, targeting $3.7B market growing 38% CAGR; LIB gets upfront, milestones and royalties. Context: expands innovative beyond derm/eye/onco-derm.
Sun Pharma Agrees U.S. MFN Pricing For Two-Year Tariff Delay
Sun Pharma Wins Favorable Lipitor Antitrust Ruling In US Appeal